{ "docId": "019de517-44b3-71b5-8a8d-243b41bb1797", "docSlug": "c77cf9536b998c2f906519be4212f807", "documentTitle": "GH Research | Investor Presentation Deck | 30 slides", "authorId": "gh-research", "authorName": "GH Research", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-11-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 23, "pageCount": 30, "prevPage": 22, "nextPage": 24, "slideType": "other", "function": "present_framework", "density": "overcrowded", "nDataPoints": 20, "notes": null, "elementsJson": null, "metadataConfidence": 0.9, "imagePath": null, "slideHref": "/slides/019de517-44b3-71b5-8a8d-243b41bb1797/23", "deckHref": "/decks/019de517-44b3-71b5-8a8d-243b41bb1797", "deckJsonHref": "/decks/019de517-44b3-71b5-8a8d-243b41bb1797.json", "deckAnchorHref": "/decks/019de517-44b3-71b5-8a8d-243b41bb1797#slide-23", "components": [ { "bbox": { "h": 0.15, "w": 0.38, "x": 0.068, "y": 0.689 }, "kind": "list", "text": "Further Results\nPharmacokinetic analyses and psychoactive effect assessments (PE Scale) support that an interval down to 1 hour between individual doses of the IDR is feasible for future clinical trials", "attrs": {}, "subkind": "bullet", "toolName": null, "toolSlug": null, "confidence": null, "componentId": "39910357-7d17-4b5f-a522-2e3580b9b9d5", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.44, "w": 0.38, "x": 0.068, "y": 0.21 }, "kind": "list", "text": "Safety Review\nNo SAEs\nAll ADRs mild\nAll ADRs resolved spontaneously\nInhalation well-tolerated\nNo noteworthy changes in vital parameters, except for temporary, non-clinically relevant increase in heart rate and blood pressure shortly after administration of GH001\nNo clinically relevant changes in ECG, safety laboratory analyses, peak flow, cognitive function, psychiatric safety assessments, including the C-SSRS", "attrs": {}, "subkind": "bullet", "toolName": null, "toolSlug": null, "confidence": null, "componentId": "6cb44cbe-eb62-4c22-96a5-592a3ecf9183", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.03, "w": 0.585, "x": 0.068, "y": 0.879 }, "kind": "source-note", "text": "SAE, Serious Adverse Event; Adverse Drug Reaction, or ADR, an adverse event with a relationship code to the investigational product of definite, probable, or possible, or where code is missing; IDR, Individualized Dosing Regimen; C-SSRS, Columbia-Suicide Severity Rating Scale; PE, Peak Experience", "attrs": {}, "subkind": null, "toolName": null, "toolSlug": null, "confidence": null, "componentId": "99e3dc36-4410-4c5a-ba2d-487ea8765632", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.03, "w": 0.15, "x": 0.78, "y": 0.879 }, "kind": "source-note", "text": "16 mg (n=1), 6-12 mg (n=3); 6-12-18 mg (n=4)\n26-12 mg (n=3); 6-12-18 mg (n=5)", "attrs": {}, "subkind": null, "toolName": null, "toolSlug": null, "confidence": null, "componentId": "d33e9fe7-8edd-4b0b-a5cf-82489e4e17a4", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.639, "w": 0.537, "x": 0.415, "y": 0.202 }, "kind": "table", "text": "ADRs, MedDRA Preferred Term, Single-dose, IDR, 6 mg (n=8), 12 mg (n=8), 18 mg (n=8), Placebo (n=6), 1h interval (n=8)1, 2h interval (n=8)2, Number of Events, Abnormal dreams, 1, Chest discomfort, 1, Crying, 2, 2, Dizziness, 1, Dry mouth, 1, Dyskinesia, 1, Fatigue, 1, 2, 1, Headache, 3, 1, 1, 1, Hypoesthesia oral, 1, Paresthesia oral, 1, Retching, Somnolence, 1, Tachycardia, 1, 2, Tension, 1, Tremor, 1", "attrs": {}, "subkind": "data", "toolName": null, "toolSlug": null, "confidence": null, "componentId": "7af59249-e5b1-4d1b-8b8c-2e867aaab734", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.04, "w": 0.86, "x": 0.068, "y": 0.104 }, "kind": "title", "text": "Single Dose and IDR – Safety and Further Results", "attrs": {}, "subkind": "headline", "toolName": null, "toolSlug": null, "confidence": null, "componentId": "4685ed7b-a486-4613-bee6-5f7a77b6f419", "frameworkName": null, "frameworkSlug": null } ], "metrics": [], "tools": [ { "name": "Table data", "slug": "table-data", "agent": null, "layer": "slide", "matchId": "a5960a22-bbbe-474b-86df-df50f366af7e", "evidence": "table/data: ADRs, MedDRA Preferred Term, Single-dose, IDR, 6 mg (n=8), 12 mg (n=8), 18 mg (n=8), Placebo (n=6), 1h interval (n=8)1, 2h interval (n=8)2, Number of Events, Abnormal dreams, 1, Chest discomfort, 1, Crying, 2", "confidence": 0.8 } ], "frameworks": [], "arcBeats": [], "loops": [ { "to": 30, "from": 5, "name": "Cost Of Inaction", "slug": "27-cost-of-inaction", "bestFor": "Urgent budget requests, compliance, risk mitigation", "matchId": "e59b812c-5781-40d1-880d-5eb666da502e", "evidence": "The document emphasizes the limitations of current treatments and the potential of GH001", "position": 0, "objective": "Highlight the need for more effective depression treatments", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "confidence": 0.6, "description": "Quantify what happens if the audience does nothing" }, { "to": 30, "from": 3, "name": "Golden Circle", "slug": "11-golden-circle", "bestFor": "Visionary leadership, brand positioning, mission statements", "matchId": "a0a779b4-6b2d-4f03-ae8f-5683cc3e54fa", "evidence": "The document presents a clear 'why' for GH001, highlighting its potential to provide ultra-rapid, durable remissions", "position": 1, "objective": "Explain why GH001 is a necessary solution", "structure": "The Why (Belief) -> The How (Process) -> The What (Result)", "confidence": 0.6, "description": "Invert the typical pitch by starting with why you exist, rather than what you do" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }